{"id":"W2000853346","doi":"10.1002/cncr.23864","title":"Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer","year":2008,"lang":"en","type":"article","venue":"Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":245,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Notre-Dame; Victoria Hospital; London Health Sciences Centre","funders":"National Cancer Institute","keywords":"Medicine; Clinical endpoint; Placebo; Urology; Peripheral edema; Prostate cancer; Internal medicine; Doubling time; Prostate; Randomized controlled trial; Prostate-specific antigen; Adverse effect; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002045937,0.001557601,0.00305496,0.0003656923,0.0005753644,0.001039711,0.001055194,0.001692179,0.009020019],"category_scores_gemma":[0.002066192,0.0006127374,0.001804822,0.0004536739,0.001022922,0.0009348397,0.0003470125,0.003005734,0.001187045],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007022035,"about_ca_system_score_gemma":0.001806793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001102237,"about_ca_topic_score_gemma":0.002651768,"domain_scores_codex":[0.99932,0.0003847692,0.00003710168,0.0001149998,0.00004994396,0.00009324408],"domain_scores_gemma":[0.998814,0.00032921,0.0003020264,0.00009835724,0.00009026104,0.0003661071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9845425,0.004655641,0.0005093032,0.0004038489,0.0007384286,0.00003657884,0.00003830031,0.0002083078,0.001574491,0.00007873469,0.0008971338,0.006316747],"study_design_scores_gemma":[0.9751689,0.02323647,0.0008035075,0.00001122227,0.0001428157,0.00002048641,0.000008598709,0.000154975,0.0001181528,0.00006745282,0.0002617167,0.000005732456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9776054,0.006199038,0.0009759485,0.001370072,0.001020743,0.007836146,0.001953676,0.0002770966,0.002761872],"genre_scores_gemma":[0.9751453,0.003140781,0.002289141,0.00279498,0.0006458111,0.01028193,0.001976414,0.00004395768,0.003681678],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009020019,"threshold_uncertainty_score":0.03017503,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01803086153307878,"score_gpt":0.3255728464527888,"score_spread":0.3075419849197101,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}